PURPOSE: To evaluate the efficacy of adjuvant systemic chemotherapy for locally advanced (pT3-4pN0/xM0) upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: We retrospectively reviewed the medical records of 109 patients with pT3-4pN0/xM0 UTUC who had undergone radical nephroureterectomy between 1996 and 2013 at our four institutions. The patients were divided into two groups: those who received adjuvant chemotherapy (AC group) and those who did not (surgery-alone: SA group). All chemotherapy regimens were cisplatin-based. Cox proportional hazards regression models addressed the associations between clinicopathological factors and recurrence-free survival (RFS) and cancer-specific survival (CSS). RESULTS: Forty-three (39.5%) out of the 109 patients underwent one to four cycles of adjuvant chemotherapy after nephroureterectomy. Median follow-up was 46.5 months. There were no significant differences in the background characteristics of the two groups, except for age. Recurrence developed in 11 (25.6%) and 29 (43.9%) patients in the AC and SA groups, respectively. Ultimately, six (14.0%) and 18 (27.3%) patients in the AC and SA groups, respectively, died of disease progression. On univariate analysis, hydronephrosis, nuclear grade, lymphovascular invasion, and adjuvant chemotherapy were significantly associated with both RFS and CSS. Charlson comorbidity index was associated only with CSS. On multivariate analysis, adjuvant chemotherapy was the only independent factor associated with improved RFS (p = 0.0178, HR = 0.41). Moreover, adjuvant chemotherapy (p = 0.0375, HR = 0.33), lower nuclear grade (p = 0.0070), and the absence of hydronephrosis (p = 0.0493) were independently associated with better CSS. CONCLUSION: Locally advanced (pT3-4pN0/xM0) UTUC patients who underwent cisplatin-based adjuvant chemotherapy demonstrated better RFS and CSS than those without adjuvant chemotherapy.
PURPOSE: To evaluate the efficacy of adjuvant systemic chemotherapy for locally advanced (pT3-4pN0/xM0) upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: We retrospectively reviewed the medical records of 109 patients with pT3-4pN0/xM0 UTUC who had undergone radical nephroureterectomy between 1996 and 2013 at our four institutions. The patients were divided into two groups: those who received adjuvant chemotherapy (AC group) and those who did not (surgery-alone: SA group). All chemotherapy regimens were cisplatin-based. Cox proportional hazards regression models addressed the associations between clinicopathological factors and recurrence-free survival (RFS) and cancer-specific survival (CSS). RESULTS: Forty-three (39.5%) out of the 109 patients underwent one to four cycles of adjuvant chemotherapy after nephroureterectomy. Median follow-up was 46.5 months. There were no significant differences in the background characteristics of the two groups, except for age. Recurrence developed in 11 (25.6%) and 29 (43.9%) patients in the AC and SA groups, respectively. Ultimately, six (14.0%) and 18 (27.3%) patients in the AC and SA groups, respectively, died of disease progression. On univariate analysis, hydronephrosis, nuclear grade, lymphovascular invasion, and adjuvant chemotherapy were significantly associated with both RFS and CSS. Charlson comorbidity index was associated only with CSS. On multivariate analysis, adjuvant chemotherapy was the only independent factor associated with improved RFS (p = 0.0178, HR = 0.41). Moreover, adjuvant chemotherapy (p = 0.0375, HR = 0.33), lower nuclear grade (p = 0.0070), and the absence of hydronephrosis (p = 0.0493) were independently associated with better CSS. CONCLUSION: Locally advanced (pT3-4pN0/xM0) UTUC patients who underwent cisplatin-based adjuvant chemotherapy demonstrated better RFS and CSS than those without adjuvant chemotherapy.
Authors: Maria Vassilakopoulou; Thibault de la Motte Rouge; Pierre Colin; Adil Ouzzane; David Khayat; Meletios-Athanasios Dimopoulos; Christos A Papadimitriou; Aristotle Bamias; Géraldine Pignot; François Xavier Nouhaud; Sophie Hurel; Laurent Guy; Pierre Bigot; Mathieu Roumiguié; Morgan Rouprêt Journal: Cancer Date: 2011-06-02 Impact factor: 6.860
Authors: Jeffrey J Leow; William Martin-Doyle; André P Fay; Toni K Choueiri; Steven L Chang; Joaquim Bellmunt Journal: Eur Urol Date: 2014-03-16 Impact factor: 20.096
Authors: Thomas Seisen; Ross E Krasnow; Joaquim Bellmunt; Morgan Rouprêt; Jeffrey J Leow; Stuart R Lipsitz; Malte W Vetterlein; Mark A Preston; Nawar Hanna; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh; Steven L Chang Journal: J Clin Oncol Date: 2017-01-03 Impact factor: 44.544
Authors: Matthew G Kaag; Rebecca L O'Malley; Padraic O'Malley; Guilherme Godoy; Mang Chen; Marc C Smaldone; Ronald L Hrebinko; Jay D Raman; Bernard Bochner; Guido Dalbagni; Michael D Stifelman; Samir S Taneja; William C Huang Journal: Eur Urol Date: 2010-06-25 Impact factor: 20.096
Authors: Kazumasa Matsumoto; Giacomo Novara; Amit Gupta; Vitaly Margulis; Thomas J Walton; Marco Roscigno; Casey Ng; Eiji Kikuchi; Richard Zigeuner; Wassim Kassouf; Hans-Martin Fritsche; Vincenzo Ficarra; Guido Martignoni; Stefan Tritschler; Joaquin Carballido Rodriguez; Christian Seitz; Alon Weizer; Mesut Remzi; Jay D Raman; Christian Bolenz; Karim Bensalah; Theresa M Koppie; Pierre I Karakiewicz; Christopher G Wood; Francesco Montorsi; Masatsugu Iwamura; Shahrokh F Shariat Journal: BJU Int Date: 2011-04-20 Impact factor: 5.588
Authors: Nicholas J Hellenthal; Shahrokh F Shariat; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Christian Bolenz; Mesut Remzi; Alon Weizer; Richard Zigeuner; Karim Bensalah; Casey K Ng; Jay D Raman; Eiji Kikuchi; Francesco Montorsi; Mototsugu Oya; Christopher G Wood; Mario Fernandez; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2009-07-17 Impact factor: 7.450
Authors: A Bamias; Ch Deliveliotis; G Fountzilas; D Gika; A Anagnostopoulos; M P Zorzou; E Kastritis; C Constantinides; P Kosmidis; M A Dimopoulos Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Carolin Blumendeller; Julius Boehme; Maximilian Frick; Martin Schulze; Antje Rinckleb; Christina Kyzirakos; Simone Kayser; Maria Kopp; Sabine Kelkenberg; Natalia Pieper; Oliver Bartsch; Dirk Hadaschick; Florian Battke; Arnulf Stenzl; Saskia Biskup Journal: J Immunother Cancer Date: 2021-01 Impact factor: 13.751